Your session is about to expire
← Back to Search
Other
2 for Migraine
N/A
Waitlist Available
Led By Laszlo L Mechtler, MD
Research Sponsored by Dent Neurologic Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 and 4 hours
Awards & highlights
Study Summary
This is a double-blinded placebo study, examining the efficacy of Sumatriptan with Naprosyn in the treatment of migraine with aura.
Eligible Conditions
- Migraine
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 and 4 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 and 4 hours
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
measure will be comparative percentage of patients pain free at 2 and 4 hours from initiating treatment with placebo vs treatment with Treximet (sumatriptan with naprosyn).
Secondary outcome measures
will be percentage of patients with pain relief at 2 and 4 hours.
Trial Design
2Treatment groups
Active Control
Placebo Group
Group I: 2Active Control1 Intervention
Sumatriptan with naprosyn taken at onset of aura associated with migraine.
Group II: 1Placebo Group1 Intervention
Placebo taken at onset of aura associated with migraine.
Find a Location
Who is running the clinical trial?
Dent Neurologic InstituteLead Sponsor
1 Previous Clinical Trials
117 Total Patients Enrolled
Laszlo L Mechtler, MDPrincipal InvestigatorDent Neurologic Institute
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger